IMRN

Immuron Ltd ADR

Immuron Ltd ADR (IMRN) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.8
Rev Growth YoY 4.8%
Gross Margin 63.7%
Price Return 3M 34.0%
Price Return 12M -34.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 1.2
ROE -39.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.4) B- (3.1) C (2.4) C- (1.9) C+ (2.5)
2026-08-04 C+ (2.7) C (2.4) B- (3.1) C (2.4) C- (1.9) C+ (2.5)
2026-08-03 C+ (2.7) C (2.4) B- (3.1) C (2.4) C- (2.0) C+ (2.5)
2026-08-02 C+ (2.7) C (2.4) B- (3.1) C (2.4) C- (1.9) C+ (2.5)